FDA Rejects Disc’s Rare Blood Disease Drug Amid Reports of Prasad’s Skepticism

The FDA in October 2025 granted bitopertin its Commissioner’s National Priority Voucher but after a shortened review time has decided the data did not support regulatory approval for treating erythropoietic protoporphyria.